The Stochastic Oscillator for NURO moved out of overbought territory on January 10, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 36 similar instances where the indicator exited the overbought zone. In of the 36 cases the stock moved lower. This puts the odds of a downward move at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NURO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NURO broke above its upper Bollinger Band on January 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on December 27, 2024. You may want to consider a long position or call options on NURO as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NURO just turned positive on December 31, 2024. Looking at past instances where NURO's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
NURO moved above its 50-day moving average on January 13, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NURO crossed bullishly above the 50-day moving average on January 13, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NURO advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.401) is normal, around the industry mean (23.475). P/E Ratio (0.000) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.717) is also within normal values, averaging (41.274).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NURO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NURO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
a developer of medical devices used for treatment of the neurological complications of diabetes
Industry MedicalSpecialties
A.I.dvisor tells us that NURO and JNDOF have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NURO and JNDOF's prices will move in lockstep.
Ticker / NAME | Correlation To NURO | 1D Price Change % | ||
---|---|---|---|---|
NURO | 100% | -2.17% | ||
JNDOF - NURO | 33% Poorly correlated | N/A | ||
SGHT - NURO | 26% Poorly correlated | -8.68% | ||
RVP - NURO | 23% Poorly correlated | -0.33% | ||
ILMN - NURO | 23% Poorly correlated | +0.87% | ||
FLMNY - NURO | 22% Poorly correlated | N/A | ||
More |